Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY24 results · Apr–Jun 2023
Astec LifeSciences reported revenue from operations of ₹142.85 crore (down 22.5% from Q1 FY23) and net loss of ₹8.19 crore for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 142.85 | 184.27 | −22.5% | 126.97 | +12.5% |
| Other income | 1.71 | 2.71 | −37.0% | 2.57 | −33.6% |
| Total income | 144.56 | 186.98 | −22.7% | 129.55 | +11.6% |
| Profit before tax | (11.01) | 15.31 | Turned loss | (6.18) | Loss widened |
| Net profit for the period | (8.19) | 11.41 | Turned loss | (4.97) | Loss widened |
| Attributable to shareholders of the company | (8.19) | 11.40 | Turned loss | (4.98) | Loss widened |
| EPS, basic (₹) | (4.18) | 5.82 | Turned loss | (2.54) | Loss widened |
| Net margin (%) | -5.7 | 6.2 | -3.9 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 142.85 | 184.27 | −22.5% | 126.97 | +12.5% |
| Other income | 1.70 | 2.71 | −37.3% | 2.57 | −33.9% |
| Total income | 144.55 | 186.97 | −22.7% | 129.54 | +11.6% |
| Profit before tax | (11.03) | 15.29 | Turned loss | (6.21) | Loss widened |
| Net profit for the period | (8.21) | 11.39 | Turned loss | (5.00) | Loss widened |
| EPS, basic (₹) | (4.19) | 5.81 | Turned loss | (2.55) | Loss widened |
| Net margin (%) | -5.7 | 6.2 | -3.9 |
Consolidated
- Filed with BSE
- 28 Jul 2023, 12:15 IST
- Board meeting
- 27 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2023, 12:15 IST
- Board meeting
- 27 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE